The D-HCM score, a new diagnostic tool for distinguishing hypertrophic cardiomyopathy from hypertensive cardiopathy.
Hypertensive heart disease
Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy diagnostic
QRS duration
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
23 Jul 2024
23 Jul 2024
Historique:
revised:
01
07
2024
received:
18
03
2024
accepted:
05
07
2024
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
aheadofprint
Résumé
The diagnosis of hypertrophic cardiomyopathy (HCM) with moderate hypertrophy is challenging. Hypertensive heart disease (HHD) is the most common differential diagnosis that mimics the LVH of HCM. The aim of this study was to compare the QRS duration in HCM and HHD to create a novel diagnostic tool to identify primary HCM. We conducted an international retrospective multicentre study enrolling patients with true HCM and HHD. A total of 547 individuals with HCM and 139 with HHD were included. The median QRS duration was significantly shorter in HCM than in HHD (88 ms [80-94] vs. 98 ms [88-108]; P < 0.01). Multivariable logistic regression identified for the novel diagnostic HCM (D-HCM) score: absence of antihypertensive drugs (+2); family history of unexplained sudden death (+2); QRS duration [<95 ms] = +1; maximum wall thickness (mm) [≥17] = +1. A cumulative QRS-HCM score ≥2 supports the diagnostic certainty of true HCM with a sensitivity of 79%, specificity of 99%, negative predictive value (NPV) of 55%, and positive predictive value (PPV) of 99%. The QRS duration in patient with HCM is significantly shorter compared with patients with HHD-related LVH. QRS duration can be used as a diagnosis marker to distinguish between HCM and HHD. The D-HCM score is a novel, simple, and accurate diagnosis tool for HCM patients with mild to moderate phenotypes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Muneretto C, Elliott P, Anastasakis A, Borger M, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733‐2779. doi:10.1093/eurheartj/ehu284
Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales‐Villa R, Basso C, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 2023;44:3503‐3626. doi:10.1093/eurheartj/ehad194
Lip GY, Felmeden DC, Li‐Saw‐Hee FL, Beevers DG. Hypertensive heart disease. A complex syndrome or a hypertensive ‘cardiomyopathy’? Eur Heart J 2000;21:1653‐1665. doi:10.1053/euhj.2000.2339
Wilson JM, Villareal RP, Hariharan R, Massumi A, Muthupillai R, Flamm SD. Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy. Tex Heart Inst J 2002;29:176‐180.
Neisius U, Myerson L, Fahmy AS, Nakamori S, el‐Rewaidy H, Joshi G, et al. Cardiovascular magnetic resonance feature tracking strain analysis for discrimination between hypertensive heart disease and hypertrophic cardiomyopathy. PLoS ONE 2019;14:e0221061. doi:10.1371/journal.pone.0221061
Schumann CL, Jaeger NR, Kramer CM. Recent advances in imaging of hypertensive heart disease. Curr Hypertens Rep 2019;21:3. doi:10.1007/s11906‐019‐0910‐6
Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu CY, et al. T1 mapping in discrimination of hypertrophic phenotypes: Hypertensive heart disease and hypertrophic cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2015;8:e003285. doi:10.1161/CIRCIMAGING.115.003285
Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998;97:48‐54. doi:10.1161/01.cir.97.1.48
Maron BJ, Haas TS, Ahluwalia A, Murphy CJ, Garberich RF. Demographics and epidemiology of sudden deaths in young competitive athletes: From the United States National Registry. Am J Med 2016;129:1170‐1177. doi:10.1016/j.amjmed.2016.02.031
Bonaventura J, Norambuena P, Tomašov P, Jindrová D, Šedivá H, Jr MM, et al. The utility of the Mayo score for predicting the yield of genetic testing in patients with hypertrophic cardiomyopathy. Arch Med Sci 2019;15:641‐649. doi:10.5114/aoms.2018.78767
Jääskeläinen P, Vangipurapu J, Raivo J, Kuulasmaa T, Heliö T, Aalto‐Setälä K, et al. Genetic basis and outcome in a nationwide study of Finnish patients with hypertrophic cardiomyopathy. ESC Heart Fail 2019;6:436‐445. doi:10.1002/ehf2.12420
Sugiura K, Kubo T, Ochi Y, Miyagawa K, Baba Y, Noguchi T, et al. Very long‐term prognosis in patients with hypertrophic cardiomyopathy: A longitudinal study with a period of 20 years. ESC Heart Fail 2022;9:2618‐2625. doi:10.1002/ehf2.13983
Boineau JP. The early repolarization variant‐‐An electrocardiographic enigma with both QRS and J‐STT anomalies. J Electrocardiol 2007;40:3.e1‐3.e10. doi:10.1016/j.jelectrocard.2006.05.001
Wolpert C, Veltmann C, Schimpf R, Antzelevitch C, Gussak I, Borggrefe M. Is a narrow and tall QRS complex an ECG marker for sudden death? Heart Rhythm 2008;5:1339‐1345. doi:10.1016/j.hrthm.2008.05.019
Domain G, Chouquet C, Réant P, Bongard V, Vedis T, Rollin A, et al. Relationships between left ventricular mass and QRS duration in diverse types of left ventricular hypertrophy. Eur Heart J Cardiovasc Imaging 2022;23:560‐568. doi:10.1093/ehjci/jeab063
Fragola PV, De Nardo D, Calò L, Cannata D. Use of the signal‐averaged QRS duration for diagnosing left ventricular hypertrophy in hypertensive patients. Int J Cardiol 1994;44:261‐270. doi:10.1016/0167‐5273(94)90290‐9
Hancock EW, Deal BJ, Mirvis DM, Okin P, Kligfield P, Gettes LS, et al. American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology, American College of Cardiology Foundation, Heart Rhythm SocietyAHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part V: Electrocardiogram changes associated with cardiac chamber hypertrophy: A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009;53:992‐1002. doi:10.1016/j.jacc.2008.12.015
Lang RM, Badano LP, Mor‐Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr 2015;28:1‐39.e14. doi:10.1016/j.echo.2014.10.003
Harrigan CJ, Peters DC, Gibson CM, Maron BJ, Manning WJ, Maron MS, et al. Hypertrophic cardiomyopathy: Quantification of late gadolinium enhancement with contrast‐enhanced cardiovascular MR imaging. Radiology 2011;258:128‐133. doi:10.1148/radiol.10090526
Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast‐enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014;130:484‐495. doi:10.1161/CIRCULATIONAHA.113.007094
Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol 1981;48:418‐428. doi:10.1016/0002‐9149(81)90068‐0
Thiele H, Paetsch I, Schnackenburg B, Bornstedt A, Grebe O, Wellnhofer E, et al. Improved accuracy of quantitative assessment of left ventricular volume and ejection fraction by geometric models with steady‐state free precession. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson 2002;4:327‐339. doi:10.1081/jcmr‐120013298
Hengel FE, Sommer C, Wenzel U. Arterial Hypertension. Dtsch Med Wochenschr 1946 2022;147:414‐428. doi:10.1055/a‐1577‐8663
Gruner C, Ivanov J, Care M, Williams L, Moravsky G, Yang H, et al. Toronto hypertrophic cardiomyopathy genotype score for prediction of a positive genotype in hypertrophic cardiomyopathy. Circ Cardiovasc Genet 2013;6:19‐26. doi:10.1161/CIRCGENETICS.112.963363
Bos JM, Will ML, Gersh BJ, Kruisselbrink TM, Ommen SR, Ackerman MJ. Characterization of a phenotype‐based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2014;89:727‐737. doi:10.1016/j.mayocp.2014.01.025
Maron BJ, Anan TJ, Roberts WC. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation 1981;63:882‐894. doi:10.1161/01.CIR.63.4.882
Hughes SE. The pathology of hypertrophic cardiomyopathy. Histopathology 2004;44:412‐427. doi:10.1111/j.1365‐2559.2004.01835.x
Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998;16:1031‐1041. doi:10.1097/00004872‐199816070‐00018
Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy‐‐pathology and pathogenesis. Histopathology 1995;26:493‐500. doi:10.1111/j.1365‐2559.1995.tb00267.x
Wicker P, Roudaut R, Haissaguere M, Villega‐Arino P, Clementy J, Dallocchio M. Prevalence and significance of asymmetric septal hypertrophy in hypertension: an echocardiographic and clinical study. Eur Heart J 1983;4:1‐5. doi:10.1093/eurheartj/4.suppl_g.1
Critoph CH, Pantazis A, Tome Esteban MT, Salazar‐Mendiguchía J, Pagourelias ED, Moon JC, et al. The influence of aortoseptal angulation on provocable left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Open Heart 2014;1:e000176. doi:10.1136/openhrt‐2014‐000176
Rodrigues JCL, Rohan S, Ghosh Dastidar A, Harries I, Lawton CB, Ratcliffe LE, et al. Hypertensive heart disease versus hypertrophic cardiomyopathy: Multi‐parametric cardiovascular magnetic resonance discriminators when end‐diastolic wall thickness ≥ 15 mm. Eur Radiol 2017;27:1125‐1135. doi:10.1007/s00330‐016‐4468‐2
Sun JP, Xu TY, Ni XD, Yang XS, Hu JL, Wang SC, et al. Echocardiographic strain in hypertrophic cardiomyopathy and hypertensive left ventricular hypertrophy. Echocardiography 2019;36:257‐265. doi:10.1111/echo.14222
Lyon A, Bueno‐Orovio A, Zacur E, Ariga R, Grau V, Neubauer S, et al. Electrocardiogram phenotypes in hypertrophic cardiomyopathy caused by distinct mechanisms: Apico‐basal repolarization gradients vs. Purkinje‐myocardial coupling abnormalities. EP Europace 2018;20:iii102‐iii112. doi:10.1093/europace/euy226